What is the efficacy of rivaroxaban for stroke prevention after embolic stroke of undetermined source?
The efficacy of rivaroxaban for stroke prevention after embolic stroke of undetermined source is supported by several studies, including the RE-SPECT ESUS trial, which showed that rivaroxaban was associated with a lower risk of stroke or systemic embolism compared to aspirin (Diener et al., 2018). The NAVIGATE ESUS trial also showed that rivaroxaban was associated with a lower risk of recurrent stroke compared to aspirin in patients with embolic stroke of undetermined source (Kasner et al., 2018). The AtRial Cardiopathy and Antithrombotic Drugs In prevention After cryptogenic stroke randomized trial also found that rivaroxaban was associated with a lower risk of stroke or systemic embolism compared to aspirin (Kamel et al., 2019). Overall, these studies suggest that rivaroxaban is an effective option for stroke prevention after embolic stroke of undetermined source. 